U.S. health insurers could sell off pharmacy-benefit managers
U.S. organ transplantation supply logistics / guidelines for use / suppliers could be better
Hospital Group Purchasing Organizations (GPOs) could be monopolies and prevent fulfillment of important medical supplies / drugs
Defense / government contractors could be tech startups / additional companies
Private equity could affect U.S. autism care / innovation
Crowdfunding / different funding sources could improve science and research
U.S. utilities could be less corrupt / better for-profit natural monopolies
Concerts could cost less
U.S. healthcare provider consolidation could raise medical costs without benefiting consumers
Too big to fail banks could be broken up
Government privatization / contracting / consulting could create inefficient spending not in the public interest
Labor unions could be organized and regulated differently to prevent corruption
Pharmaceutical industry acquisitions could inhibit drug innovation and raise drug prices
Corporate monopolies could be broken up or more regulated
Credit reports / background checks could be more accurate
Tech companies and the internet could be regulated
Medical software could be easier / quicker / inter-operable
Institutional investors could threaten competition
NRSRO designation could be removed from SEC rules